# OnCo record nct05458297 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05458297/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05458297", "NCT05458297" ;
  schema:name "A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-"@en ;
  schema:description "A phase 2 trial of Zilovertamab vedotin, Nemtabrutinib in mantle cell lymphoma and follicular lymphoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05458297/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05458297> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2022-07-21" ;
  onco:cancers <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/follicular-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:drugs <https://onco.cc/drugs/zilovertamab-vedotin/>, <https://onco.cc/drugs/nemtabrutinib/> ;
  onco:companies <https://onco.cc/companies/merck/> .